Strong results announced for new LRRK2 inhibitor clinical trial for Parkinson’s

News

Author: Parkinson's Life editorsPublished: 10 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Conceptual illustration of neuron cells with glowing link knots. Synapse and Neuron cells sending electrical chemical signals. Neuron of Interconnected neurons with electrical pulses, 3D rendering

The pharmaceutical company Denali Therapeutics has announced strong positive results from the first in-human LRRK2 inhibitor clinical trial.

The treatment lowers LRRK2 protein activity in body cells, which could ultimately have the potential to slow – or stop – Parkinson’s progression.

The small molecule inhibitor of LRRK2, called DNL201, achieved an average of more than 90% inhibition of LRRK2 kinase activity observed at peak.

Dr Ryan Watts, PhD, CEO of Denali Therapeutics, said: “Mutations in LRRK2 are a major risk factor for Parkinson’s disease. Targeting this degenogene represents a promising approach to develop disease modifying medicines for patients suffering from this terrible disease.”

He continued: “By restoring LRRK2 activity to normal levels, we believe we can reverse lysosomal dysfunction, which could potentially benefit both patients with LRRK2 mutations, as well as idiopathic Parkinson’s disease patients who exhibit lysosomal dysfunction.”

Go Back

Share this story

Comments


Related articles


100 For Parkinson's lead

Special reports

High blood pressure, arthritis and depression are most common conditions in Parkinson’s patients

“We cannot gather too much data”

READ MORE
Aerial view of various coffee

Global update

Parkinson’s in the news: October

This month’s top Parkinson’s disease news stories from around the globe

READ MORE
Michael J Fox book cover

Global update

Michael J Fox opens up about living with Parkinson’s disease

The ‘Back to the Future’ star discusses his latest book

READ MORE